Olema reports Q3 2026 results, reiterates early-2027 OPERA-01 data timelineNov 16Regulatory decisionOlema Pharmaceuticals, Inc.palazestrant
Amgen posts results for terminated acapatamab mCRPC trial; updates MARITIME-PEN and AMG 691 recordsNov 13Weekly roundup, 6 itemsacapatamabAMG-691Updated
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
Lilly posts Phase 3 results for orforglipron and lebrikizumab; discloses abemaciclib trial haltOct 16Weekly roundup, 7 itemsabemaciclibBayerUpdated
Fred Hutchinson posts Phase II acalabrutinib results; AstraZeneca's AZD0780 LDL-C trial completesOct 16Weekly roundup, 11 itemsacalabrutinibAstraZenecaUpdated
Pfizer registers real-world observational study of marstacimab in hemophilia A and B patientsOct 9Weekly roundup, 8 itemsabrocitinibcyclophosphamide
Vir Biotechnology says FDA grants Fast Track to VIR-5500 for prostate cancerOct 8Regulatory milestoneAstellas PharmaVir Biotechnology, Inc.
Bayer registers India observational study of darolutamide in mHSPCSep 9Weekly roundup, 2 itemsBayerdarolutamide
FDA approves ZAVZPRET label update; Pfizer registers RSVpreF and prostate cancer studiesAug 21Weekly roundup, 7 itemsBioNTech SEPenbraya
Olema completes OPERA-01 enrollment, pushes top-line data to Q1 2027Aug 10Quarterly updateOlema Pharmaceuticals, Inc.
Janux reports Q2 2026 results, keeps prostate cancer and autoimmune programs on trackAug 6Quarterly updateJanux TherapeuticsJANX007
Vir reports Week 96 SOLSTICE data, ECLIPSE program fully enrolled, VIR-5500 expansion underwayAug 5Quarterly updateVir Biotechnology, Inc.VIR-5500
ORIC Pharmaceuticals starts Phase 3 Himalayas-1 trial, adds Bayer supply dealAug 3Quarterly updateORIC Pharmaceuticals
ORIC Pharmaceuticals registers Phase 3 Himalayas-1 trial for rinzimetostat in mCRPCJul 23Trial updateBayerdarolutamide